Tsinghua University

Gp Medical, Inc.

Other

Baxter International Inc.

Challenge Bioproducts Co., Ltd.

Hsing-Wen Sung

Hosheng Tu

Kiran Sonaje

Er-Yuan Chuang

Yu-Hsin Lin

Hsiang-Fa Liang

Mei-Chin Chen

Ho-Ngoc Nguyen

Zi-Xian Liao

Ha Giang Thi Nguyen

Huang-Chien Liang

Fang Yi Su

Po-Yen Lin

Min-Fan Chung

Ko-Jie Chen

Shu-Fen Peng

Po-Wei Lee

Roger H Tu

Shih-Hwa Shen

Chieh-Cheng Huang

Cary Hata

Yang-Bao Miao

Wei-Chih Lin

Kuan-Hung Chen

Chun-Wen Hsiao

Po-Yuan Cheng

Wen-Hsiang Chang

Li-Wen Hsu

Peter Y Tu

Ting-Fan Yang

Chin-Tsung Huang

Wei-Lin Wan

Wei-Lun Chiang

Hung-Kun Hsu

Meng-Hsuan Hsieh

Thomas Chau-Jen Lee

Ching-Kuan Lin

Po-Chien Shih

Po-Kai Luo

Wen-Yu Pan

Hsin-Yi Hu

Po-Ming Chen

Shu-Jyuan Lin

Er-Yuan Chung

Cherng-Jyh Ke

A spiky metal organic framework is provided in the present disclosure. The spiky metal organic framework is formed by a coordination reaction between at least one metal ion and an organic ligand, and includes a body and a plurality of spike-like structures. The body is a spherical shape, and a particle size of the body is 1 &#x3bc;m to 3 &#x3bc;m. The spike-like structures are distributed on a surface of the body, a diameter of each spike-like structure is 15 nm to 35 nm, and a length of each spike-like structure is 250 nm to 400 nm.

Spiky metal organic framework, method for fabricating thereof, and kit for treating cancer

The present disclosure provides an oral drug composition including a prodrug and a carrier. The prodrug bonds an active drug to a spacer with a covalent bond, in which the spacer has a disulfide bond. The carrier is for carrying the prodrug with an efficient amount, and the carrier includes a &#x3b2;-1,3-D-glucan.

Oral drug composition and use thereof

The present disclosure provides a sustained-release composition including a sodium hydrosulfide and a carrier. The carrier is provided for carrying the sodium hydrosulfide with an effective amount and includes a first component and a second component. The first component includes a paraffin wax, and the second component includes a fatty alcohol, a fatty acid or a phospholipid. The present disclosure also provides a method for fabricating the sustained-release composition. The method includes providing a first solution, providing the carrier, providing a second solution, performing an oil-in-water emulsification, and cooling the emulsion. In addition, the present disclosure provides a method for treating the chronic wounds. The method includes administering an effective amount of the aforementioned sustained-release composition to a subject suffered from the chronic wounds.

Sustained-release composition, method for fabricating, and use thereof

A sustained-release composition is provided in the present disclosure for producing a therapeutic gas, such as hydrogen sulfide or hydrogen. The sustained-release composition includes a precursor and a carrier. The precursor is diallyl trisulfide or magnesium, and the carrier includes a poly lactic-co-glycolic acid copolymer for carrying the precursor with an efficient amount.

The present invention provides a nano/micro bubble system for drug delivery comprising a gas core, a plurality of surfactants and an active ingredient. The surfactants surround the gas core and form a double-layer structure having an inner layer and outer layer. The active ingredient is embedded in a gap formed between the inner layer and the outer layer of the double-layer structure and comprises a nucleic acid, a peptide or a protein.

Nano / micro bubbles for drug delivery

An (acid-substituted polyaniline)-grafted hydrogel copolymer is provided. The (acid-substituted polyaniline)-grafted hydrogel copolymer has a general formula as below: wherein A is a proton acid group, m and n are same or different integers greater than 0, x is an integer equal to or greater than 0, and y is an integer equal to or greater than 1, provided that x and y are the same or different at each occurrence, and at least an x is not 0. The (acid-substituted polyaniline)-grafted hydrogel copolymer is formed by the polymerization and substitution reaction between chitosan, polyaniline, and proton acid. The (acid-substituted polyaniline)-grafted hydrogel copolymer behaves as a pH-responsive hydrogel with photo-thermal properties and can be applied to photo-thermal therapy.

Acid-substituted polyaniline-grafted hydrogel copolymer and use thereof

The pharmaceutical composition includes a drug layer comprising an active ingredient, a surfactant, an acidic component and an effervescent ingredient. The active ingredient comprises a nucleic acid, a peptide or a protein. The acidic component and effervescent ingredient of the drug layer are dissolved in the water to react for generating carbon dioxide and bubbles thereof. The surfactants surround the carbon dioxide gas core and form a double-layer structure having an inner layer and outer layer. The active ingredient is embedded in a gap formed between the inner layer and the outer layer of the double-layer structure.

Pharmaceutical composition for preparing drug delivery nano/micro bubbles

A method for oral administration of an active ingredient to a subject is provided whereby a plurality of bubbles containing the active ingredient t are formed in a small intestinal of the subject. The method includes administering orally to the subject an effective amount of the above-mentioned pharmaceutical composition. The pharmaceutical composition includes a drug layer and an enteric coating layer. The drug layer comprises an active ingredient, a surfactant, an acidic component and an effervescent ingredient. The active ingredient comprises a nucleic acid, a peptide or a protein. When the acidic component of the drug layer is dissolved in the small intestinal to react with the effervescent ingredient for generating carbon dioxide and the plurality of bubbles containing the active ingredient, and the active ingredient is embedded in a gap formed between an inner layer and an outer layer of an double-layer structure formed by the surfactant.

Method for oral administration of an active ingredient

The invention discloses use of a pharmaceutical composition for slow-release delivery of a bioactive agent, comprising mixing the bioactive agent with a partially hydrophobic chitosan solution at a low pH and delivering the hydrogel at a physiological pH to transform the hydrogel to a solid complex for releasing the bioactive agent. The partially hydrophobic chitosan is characterized by presence of alternating charges of protonated amine groups and hydrophobic side groups.

Pharmaceutical composition of nanoparticles

The invention discloses a pharmaceutical composition of pH-sensitive liposome nanoparticles for lodging in a target tissue cell in situ of an animal subject, the nanoparticles comprising a proton-releasing photosensitive compound that releases protons upon photolysis, wherein the compound is in vesicles of the liposomes. A light or UV light is provided to induce the photosensitive compound to release the protons, thus the released protons causing the pH-sensitive liposome to decompose.

The invention discloses a pharmaceutical composition of nanoparticles consisting of chitosan, a negatively charged substrate, and at least one bioactive agent that is encapsulated within cucurbiturils for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.

The invention discloses a composition of nanoparticles composed of positively charged chitosan, one negatively charged substrate, and optionally a zero-charge compound or at least one tumor necrosis factor inhibitor for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.

The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one DNA, RNA or bioactive agent characterized with a positive surface charge and their enhanced efficiency for gene delivery and bioactive agent delivery.

Nanoparticles for delivery of bioactive agents

The invention discloses the nanoparticles composed of chitosan, poly-&#x3b3;-glutamic acid, and at least one bioactive agent characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery.

Nanoparticles for protein drug delivery

The invention discloses a pharmaceutical composition of multifunctional core-shell nanoparticles, each nanoparticle comprising: a core portion comprised of hydrophobic poly(D,L-lactic-co-glycolic acid) (PLGA) and a detection-enhancing substance, and a shell portion comprised of positively charged chitosan adapted to cause no aggregation of nanoparticles due to electrostatic repulsion between the positively charged nanoparticles. In one embodiment, the detection-enhancing substance includes SPIO, a quantum dot, a fluorescent quantum dot, a bubble, an air bubble, and the like.

Growing community of inventors

Hsinchu, Taiwan

Hsing-Wen Sung